July 31, 2024 04:01 PM Eastern Daylight Time LAGUNA HILLS, Calif. & NEW YORK–(BUSINESS WIRE)–Adagio Medical, Inc. (“Adagio Medical”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD; or “ARYA IV”), […]
Tag: Adagio Medical
Adagio Medical Announces First European Commercial Procedures and Commencement of U.S. FDA Pivotal IDE for Ventricular Tachycardia Cryoablation System
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical, Inc. (“Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies for ventricular tachycardia (“VT”) and atrial fibrillation (“AF”), today announced the completion of the first commercial procedures using its recently CE-Marked VT Cryoablation System and the U.S. Food and Drug Administration […]
Adagio Medical Announces CE Mark approval of VT Cryoablation System, Plans for Immediate Commercialization in Select European Centers
LAGUNA HILLS, Calif., March 25, 2024 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for ventricular tachycardia (“VT”) and atrial fibrillation (“AF”), today announced CE Mark approval of its ultra-low temperature cryoablation (“ULTC”) system for the treatment of monomorphic ventricular tachycardia. The system consists of the upgraded cryoablation console, […]
Adagio Medical Announces Initiation and First Procedure in FULCRUM-VT Trial, Starting The Process For Bringing Ultra-Low Temperature Cryoablation for Ventricular Arrhythmias to US Market
LAGUNA HILLS, Calif., Sept. 14, 2023 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the first ultra-low temperature cryoablation (ULTC) procedure performed using the Adagio vCLAS™ catheter system in the United States as part of the FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation for Recurring Monomorphic Ventricular Tachycardia) clinical trial, NCT # […]
Adagio Medical Announces Completion of Enrollment in Cryocure-VT Trial, Maps the Pathway to CE-Mark of vCLAS™ VT Ablation Catheter
LAGUNA HILLS, Calif., May 3, 2023 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the completion of enrollment in its Cryocure-VT trial (NCT # 04893317) of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic ventricular tachycardias. 60 patients […]
Adagio Medical Announces Initiation and First Patient Enrollment in PARALELL Trial To Investigate Safety and Performance of CryoPulse™ Catheter System for Pulsed Field Ablation and Pulsed Field Cryoablation of Persistent Atrial Fibrillation
LAGUNA HILLS, Calif. , Oct. 24, 2022 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced its first pulsed field cryoablation (PFCA) procedure performed using the Adagio CryoPulse™ catheter system as part of the PARALELL (Pulsed Field Ablation and Pulsed Field CRyoAbLation […]
Adagio Medical Announces Publication of Cryocure-2 Data Reporting 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Discusses Current Status of iCLAS™ Cryoablation System
LAGUNA HILLS, Calif., July 28, 2022 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the publication of the results of its Cryocure-2 ultra-low temperature cryoablation (ULTC) study in patients with AF in the Journal of American College of Cardiology […]
Adagio Medical Reports 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Presents Recent Developments of Pulsed Field Cryoablation Technology
LAGUNA HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the results of its CryoCure-2 ultra-low temperature cryoablation (ULTC) prospective multi-center study in patients with AF at the 2021 Heart Rhythm Society Annual Meeting. The late-breaking […]
Adagio Medical, Inc., reports pre-clinical effectiveness combining their existing ultra-low temperature cryoablation catheter with Pulsed Field Ablation (PFA) in a single Pulsed Field Cryoablation (PFCA) catheter
LAGUNA HILLS, Calif., Aug. 3, 2020 /PRNewswire/ — Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AFib) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced successful pre-clinical results demonstrating their existing cryoablation catheter is also capable of ablating the tissue through pulsed field ablation (PFA) delivered […]
Adagio Medical Announces US FDA Investigational Device Exemption Approval With Conditions To Conduct A Clinical Study For Treatment Of Persistent Atrial Fibrillation Using The Ultra-Low Temperature Cryoablation System
LAGUNA HILLS, Calif., Aug. 19, 2019 /PRNewswire/ — Adagio Medical, Inc. (Adagio), the developer of iCLAS™, the company’s ultra-low temperature intelligent continuous lesion ablation system, announced that it has received an Investigational Device Exemption approval with conditions from the US Food and Drug Administration (FDA) to conduct a non-randomized, single-arm clinical study for persistent atrial […]